Cytotoxic activity of normal mouse serum on mouse tumor cells in vitro. 1998

Y Tanigaki, and N Terada, and H Kitamura, and E Kitano, and K Takemura, and T Yamamoto, and Y Mori, and H Akedo, and H Tanaka
Department of Cell Biology, Osaka Medical Center for Cancer and Cardiovascular Diseases, 3-3, 1 Chome, Nakamichi, Higashinari-ku, Osaka, 537-8511, Japan.

Cytotoxic effects of normal mouse serum on mouse tumor cells were investigated in vitro. When FE melanoma cells of C57BL/6 mouse origin, were cultured in medium containing 1% fetal calf serum (FCS) and 10-30% C57BL/6 mouse serum, number of viable FE cells markedly decreased after a little increase in their number, indicating cell death of FE cells in culture with mouse serum. Phase-contrast microscopic examination showed appearance of fatty degeneration in FE cells after 24 h, and an increase in cell death after 48 h. Electron microscopic examination, and agarose gel electrophoresis of DNA at 72 h of culture showed that their cell death occurred as necrosis. This cytotoxic effect of mouse serum was also found in culture of combinations of C57BL/6 mouse serum and C57BL/6 mouse melanoma cells (G6 cells), and BALB/c mouse serum and various BALB/c mouse tumor cells (G-5 and G-1 liver tumor cells, and Colon 26 cells). Furthermore, sera of BALB/c and B10D2 mice also showed the cytotoxic effect on FE cells. The cytotoxic effect of mouse serum was not ascribed to complement activity because all mouse sera were treated at 56 degrees C for 30 min before use, and this heat treatment completely abolished complement activity, and because serum of C5-deficient mice also showed the cytotoxic effect. This cytotoxic activity was stable at heat treatment at 100 degrees C for 10 min, and was in a serum fraction of molecular weights more than 30,000 dalton. The present results show that normal mouse serum has a factor(s) inducing fatty degeneration and necrosis of mouse tumor cells.

UI MeSH Term Description Entries
D008546 Melanoma, Experimental Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA. B16 Melanoma,Melanoma, B16,Melanoma, Cloudman S91,Melanoma, Harding-Passey,Experimental Melanoma,Experimental Melanomas,Harding Passey Melanoma,Melanomas, Experimental,B16 Melanomas,Cloudman S91 Melanoma,Harding-Passey Melanoma,Melanoma, Harding Passey,Melanomas, B16,S91 Melanoma, Cloudman
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D008858 Microscopy, Phase-Contrast A form of interference microscopy in which variations of the refracting index in the object are converted into variations of intensity in the image. This is achieved by the action of a phase plate. Phase-Contrast Microscopy,Microscopies, Phase-Contrast,Microscopy, Phase Contrast,Phase Contrast Microscopy,Phase-Contrast Microscopies
D002452 Cell Count The number of CELLS of a specific kind, usually measured per unit volume or area of sample. Cell Density,Cell Number,Cell Counts,Cell Densities,Cell Numbers,Count, Cell,Counts, Cell,Densities, Cell,Density, Cell,Number, Cell,Numbers, Cell
D002467 Cell Nucleus Within a eukaryotic cell, a membrane-limited body which contains chromosomes and one or more nucleoli (CELL NUCLEOLUS). The nuclear membrane consists of a double unit-type membrane which is perforated by a number of pores; the outermost membrane is continuous with the ENDOPLASMIC RETICULUM. A cell may contain more than one nucleus. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed) Cell Nuclei,Nuclei, Cell,Nucleus, Cell
D003182 Complement C5 C5 plays a central role in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C5 is cleaved by C5 CONVERTASE into COMPLEMENT C5A and COMPLEMENT C5B. The smaller fragment C5a is an ANAPHYLATOXIN and mediator of inflammatory process. The major fragment C5b binds to the membrane initiating the spontaneous assembly of the late complement components, C5-C9, into the MEMBRANE ATTACK COMPLEX. C5 Complement,Complement 5,Complement C5, Precursor,Complement Component 5,Precursor C5,Pro-C5,Pro-complement 5,C5, Complement,C5, Precursor,C5, Precursor Complement,Complement, C5,Component 5, Complement,Precursor Complement C5,Pro C5,Pro complement 5
D003593 Cytoplasm The part of a cell that contains the CYTOSOL and small structures excluding the CELL NUCLEUS; MITOCHONDRIA; and large VACUOLES. (Glick, Glossary of Biochemistry and Molecular Biology, 1990) Protoplasm,Cytoplasms,Protoplasms
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA
D004587 Electrophoresis, Agar Gel Electrophoresis in which agar or agarose gel is used as the diffusion medium. Electrophoresis, Agarose Gel,Agar Gel Electrophoresis,Agarose Gel Electrophoresis,Gel Electrophoresis, Agar,Gel Electrophoresis, Agarose

Related Publications

Y Tanigaki, and N Terada, and H Kitamura, and E Kitano, and K Takemura, and T Yamamoto, and Y Mori, and H Akedo, and H Tanaka
April 1959, Transplantation bulletin,
Y Tanigaki, and N Terada, and H Kitamura, and E Kitano, and K Takemura, and T Yamamoto, and Y Mori, and H Akedo, and H Tanaka
May 1978, Journal of immunology (Baltimore, Md. : 1950),
Y Tanigaki, and N Terada, and H Kitamura, and E Kitano, and K Takemura, and T Yamamoto, and Y Mori, and H Akedo, and H Tanaka
June 1960, British journal of cancer,
Y Tanigaki, and N Terada, and H Kitamura, and E Kitano, and K Takemura, and T Yamamoto, and Y Mori, and H Akedo, and H Tanaka
December 1958, A.M.A. archives of pathology,
Y Tanigaki, and N Terada, and H Kitamura, and E Kitano, and K Takemura, and T Yamamoto, and Y Mori, and H Akedo, and H Tanaka
September 1978, Journal of the National Cancer Institute,
Y Tanigaki, and N Terada, and H Kitamura, and E Kitano, and K Takemura, and T Yamamoto, and Y Mori, and H Akedo, and H Tanaka
June 1981, The Japanese journal of experimental medicine,
Y Tanigaki, and N Terada, and H Kitamura, and E Kitano, and K Takemura, and T Yamamoto, and Y Mori, and H Akedo, and H Tanaka
February 1974, European journal of immunology,
Y Tanigaki, and N Terada, and H Kitamura, and E Kitano, and K Takemura, and T Yamamoto, and Y Mori, and H Akedo, and H Tanaka
December 1974, Canadian journal of microbiology,
Y Tanigaki, and N Terada, and H Kitamura, and E Kitano, and K Takemura, and T Yamamoto, and Y Mori, and H Akedo, and H Tanaka
March 2002, Chemotherapy,
Y Tanigaki, and N Terada, and H Kitamura, and E Kitano, and K Takemura, and T Yamamoto, and Y Mori, and H Akedo, and H Tanaka
August 1977, Journal of immunology (Baltimore, Md. : 1950),
Copied contents to your clipboard!